mp.weixin.qq.com· 鼎泰集团TriApex·· 2026-09-14PickScore69
Parallel Phase III Trials Show B7-H3 ADCs Cut Death Risk in Relapsed Small Cell Lung Cancer
WCLC 2026｜两项 B7-H3 ADC 复发小细胞肺癌 Ⅲ 期研究 TAISHAN-302 与 ARTEMIS-008 的平行比较
In brief
Two Phase III trials of B7-H3 antibody-drug conjugates in second-line relapsed small cell lung cancer, TAISHAN-302 and ARTEMIS-008, both hit their primary overall survival endpoint against topotecan, and TAISHAN-302 was published simultaneously in the New England Journal of Medicine. Reported back to back at WCLC 2026, the trials yielded identical OS hazard ratios of 0.46 (95% CI 0.35-0.62), providing independent, replicable Phase III evidence that B7-H3 ADCs beat current standard treatment in this setting.
Why it matters
Two independent Phase III trials produced the same OS hazard ratio of 0.46 for B7-H3 ADCs in relapsed SCLC.
Source: mp.weixin.qq.com · mp.weixin.qq.com